Sanctuary Advisors LLC Has $2.17 Million Stake in Hims & Hers Health, Inc. $HIMS

Sanctuary Advisors LLC decreased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 18.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 104,678 shares of the company’s stock after selling 23,438 shares during the quarter. Sanctuary Advisors LLC’s holdings in Hims & Hers Health were worth $2,173,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the third quarter valued at about $28,000. Silicon Valley Capital Partners acquired a new position in Hims & Hers Health in the 3rd quarter valued at approximately $48,000. Flagship Harbor Advisors LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at approximately $28,000. Bogart Wealth LLC raised its holdings in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Hims & Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insiders Place Their Bets

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the sale, the chief operating officer directly owned 432,124 shares in the company, valued at $13,611,906. This represents a 3.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David B. Wells acquired 48,400 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were bought at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the purchase, the director directly owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. This represents a 27.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold 83,126 shares of company stock worth $2,711,339 over the last quarter. Corporate insiders own 11.76% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent research reports. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Needham & Company LLC upped their target price on Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. TD Cowen reduced their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating for the company in a research report on Friday, March 27th. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $30.70.

Hims & Hers Health Stock Up 0.3%

Shares of HIMS opened at $32.79 on Wednesday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The company has a 50-day moving average price of $30.37 and a two-hundred day moving average price of $26.34. The stock has a market cap of $7.59 billion, a price-to-earnings ratio of -364.36, a P/E/G ratio of 92.03 and a beta of 2.35. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company had revenue of $608.10 million during the quarter, compared to the consensus estimate of $616.84 million. During the same quarter in the prior year, the company posted $0.20 earnings per share. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. Equities analysts predict that Hims & Hers Health, Inc. will post 0.03 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.